Journal Home
Search for

Articles in Press

Return to articles in press list

Prevalence of Bone Mineral Density Abnormalities and Related Risk Factors in an Ambulatory HIV Clinic Population

Silvia Guillemi12Corresponding Author Informationemail address, Marianne Harris23, Gregory P. Bondy24, Francisco Ng3, Wendy Zhang1, Viviane D. Lima1, Clara E. Michaels3, Allan Belzberg5, Julio S. Montaner12

Received 2 December 2009; received in revised form 28 May 2010; accepted 1 June 2010. published online 22 July 2010.
Corrected Proof

Abstract 

Bone mineral density (BMD) abnormalities are observed frequently among human immunodeficiency virus (HIV)-infected patients. Risk factors for reduced BMD in the setting of HIV have been previously studied, but detailed antiretroviral treatment history is often not available. A cross-sectional observational study was conducted between 2005 and 2007 among unselected HIV-infected adults attending an ambulatory urban HIV clinic. Dual-energy X-ray absorptiometry (DXA) scans of lumbar spine and femoral neck, full laboratory profile, detailed questionnaire, and antiretroviral history were obtained. Univariate and multivariate logistic regression analyses were performed to investigate factors associated with BMD below the expected range for age. Two hundred ninety patients completed the study: 80% Caucasians, 89% males, with median age of 49yr. Low BMD as assessed by Z-score was present in 19.7% of the patients. By multivariate analysis, only lower body mass index (BMI) was an independent risk factor for low BMD. Cumulative exposure to protease inhibitors, non-nucleosides, and individual nucleoside and nucleotide analogs were not independently associated with low BMD. In conclusion, a 19.7% prevalence of abnormal BMD by DXA scan was identified in an unselected group of HIV-infected adults. Lower BMI was independently associated with low BMD. No correlation was found between abnormal BMD and cumulative exposure to any antiretroviral agents.

1 British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

2 University of British Columbia, Vancouver, British Columbia, Canada

3 AIDS Research Program, Providence Health Care, Vancouver, British Columbia, Canada

4 Lipid/Vascular Risk Reduction Clinic, Providence Health Care, Vancouver, British Columbia, Canada

5 Department of Nuclear Medicine, Providence Health Care, Vancouver, British Columbia, Canada

Corresponding Author InformationAddress correspondence to: Silvia Guillemi, MD, B526 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.

 This project was supported by a grant from GlaxoSmithKline Canada.

PII: S1094-6950(10)00197-6

doi:10.1016/j.jocd.2010.06.001